BioLineRx to Start BL-8040 Study - Analyst Blog
April 16 2013 - 2:30PM
Zacks
BioLineRx (BLRX) recently received approval in
the US for the initiation of a multi-center, open-label phase IIa
study on BL-8040. BioLineRx is looking to develop BL-8040 for the
treatment of acute myeloid leukemia (AML) and other types of
hematological cancers.
The study will evaluate the safety and efficacy of repeated
escalating doses of BL-8040 in adults suffering from
relapsed/refractory AML. Secondary endpoints include
pharmacokinetic profile of the candidate and an efficacy
evaluation.
BioLineRx expects partial results in the fourth quarter of 2013,
while the final results are expected in the second half of
2014.
We remind investors that in Sep 2012, the rights to BL-8040 were
in-licensed by the company from Biokine Therapeutics Ltd.
As per BioLineRx, approximately 250,000 adults worldwide are
diagnosed with AML every year. In spite of efforts being made to
develop therapies for AML, less than 25% of patients survive 5
years after being diagnosed with the disease.
Currently available treatments include chemotherapy, radiation
therapy and stem cell transplantation. Eisai Co.,
Ltd. (ESALY) and Johnson & Johnson
(JNJ) are together trying to develop Dacogen (decitabine) for
AML.
BioLineRx, a biopharmaceutical company, carries a Zacks Rank #3
(Hold). We remind investors that the company suffered a pipeline
setback recently with disappointing interim results being reported
from the phase II/III CLARITY trial of BL-1020, being developed for
the treatment of schizophrenia. The interim analysis indicated that
the study will not meet its primary endpoint.
Companies like UCB (UCBJF) look well-positioned
in the biopharma space. UCB carries a Zacks Rank #1 (Strong
Buy).
BIOLINE RX LTD (BLRX): Get Free Report
EISAI CO LTD (ESALY): Get Free Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Sep 2023 to Sep 2024